Send to

Choose Destination
Int J Oncol. 2014 Apr;44(4):1032-40. doi: 10.3892/ijo.2014.2259. Epub 2014 Jan 15.

The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).

Author information

Department of Minimally Invasive Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China.


Among the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives many of the cancer 'hallmarks' through downstream activation of the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling pathway. Additionally, dysregulation of the interleukin (IL)-6-mediated JAK/STAT3 signaling pathway is closely related to the development of diverse human solid tumors including colorectal cancer (CRC). On this basis, modulation of the IL-6/JAK/STAT3 signaling pathway is currently being widely explored to develop novel therapies for CRC. The present review details the mechanisms and roles of the IL-6/JAK/STAT3 pathway in CRC, describes current therapeutic strategies, and the search for potential therapeutic approaches to treat CRC.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Spandidos Publications
Loading ...
Support Center